Unknown

Dataset Information

0

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.


ABSTRACT: RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ?65 years (n?=?269) were randomized 1:1 to once-daily ibrutinib 420?mg continuously or chlorambucil 0.5-0.8?mg/kg for ?12 cycles. With a median (range) follow-up of 60 months (0.1-66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%; HR [95% CI]: 0.146 [0.098-0.218]; OS estimates at 5 years: 83% vs 68%; HR [95% CI]: 0.450 [0.266-0.761]). Ibrutinib benefit was also consistent in patients with high prognostic risk (TP53 mutation, 11q deletion, and/or unmutated IGHV) (PFS: HR [95% CI]: 0.083 [0.047-0.145]; OS: HR [95% CI]: 0.366 [0.181-0.736]). Investigator-assessed overall response rate was 92% with ibrutinib (complete response, 30%; 11% at primary analysis). Common grade ?3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%), and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time. Fifty-eight percent of patients continue to receive ibrutinib. Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus chlorambucil and increased depth of response over time.

SUBMITTER: Burger JA 

PROVIDER: S-EPMC7214263 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications


RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or chlorambucil 0.5-0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1-66), progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS estimates at 5 years: 70% vs 12%;  ...[more]

Similar Datasets

| S-EPMC9198904 | biostudies-literature
| S-EPMC4400288 | biostudies-literature
| S-EPMC5770586 | biostudies-literature
| S-EPMC6119145 | biostudies-literature
| S-EPMC6509542 | biostudies-literature
| S-EPMC9635026 | biostudies-literature
| S-EPMC6899718 | biostudies-literature
| S-EPMC5437732 | biostudies-literature
| S-EPMC5969380 | biostudies-literature
| S-EPMC8913448 | biostudies-literature